Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTRAY EXTENSION: Open-label Extension Study of Sotatercept (MK-7962) in Pulmonary Arterial Hypertension
jRCT2061250021Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study intervention due to an adverse event. Started Jul 2025; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2061250021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250021.